Phase III dupilumab data show significant improvements in atopic dermatitis

Treatment with dupilumab resulted in significant clinical improvements in adults with inadequately controlled moderate to-severe atopic dermatitis, in two phase III studies evaluating the biologic agent, according to Regeneron and Sanofi. The phase III results of the two 16-week studies, <a...
Source: Skin and Allergy News - Category: Dermatology Source Type: news